-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: To elucidate the prevalence of rheumatologist-verified diagnosis of axial spondyloarthritis (RVD-axSpA) in patients with chronic back pain presenting to routine secondary inflammatory bowel disease (IBD) outpatient clinics prevalence
METHODS: A screening questionnaire was sent to consecutive patients at the IBD clinic of a university teaching hospital and included for rheumatology evaluation in the following population—patients who met eligibility criteria (diagnosed by a gastroenterologist, 18-80 years old, no Receiving biological therapy, no prior axSpA diagnosis); population with moderate probability of axSpA diagnosis [self-reported chronic back pain (CBP) >3 months, onset <45 years]
Contents include medical review, physical examination, patient-reported outcome measures, human leukocyte antigen B27, C-reactive protein, pelvic radiographs, and axSpA protocol magnetic resonance imaging
RESULTS: Of the 470 patients contacted, 91 had self-reported CBP >3 months and onset <45 years, of whom 82 were eligible for clinical evaluation
For patients with undiagnosed RVD axSpA (self-reported CBP, incidence <45 years) attending an IBD clinic in a secondary care facility, the prevalence was estimated at 5% (95% CI 1.
Conclusions: There is a significant axSpA recessive disease burden in IBD patients
Source:
Lim CSE, Tremelling M, Hamilton L, et al.
